Literature DB >> 31238085

Increased risk of second primary malignancies in patients with mycosis fungoides: A single-center cohort study.

Amrita Goyal1, Daniel O'Leary2, Kavita Goyal3, Nathan Rubin4, Kimberly Bohjanen3, Maria Hordinsky3, Steven T Chen5, Lyn M Duncan6, Georgios Pongas7, Aleksandr Lazaryan8.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 31238085      PMCID: PMC6940541          DOI: 10.1016/j.jaad.2019.06.037

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  4 in total

1.  Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.

Authors:  Kathie P Huang; Martin A Weinstock; Christina A Clarke; Alex McMillan; Richard T Hoppe; Youn H Kim
Journal:  Arch Dermatol       Date:  2007-01

2.  Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma.

Authors:  B N Lee; M Duvic; C K Tang; C Bueso-Ramos; Z Estrov; J M Reuben
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

3.  Refractory seborrheic dermatitis of the head in a patient with malignant lymphoma.

Authors:  Kayo Okada; Yuichiro Endo; Akihiro Fujisawa; Miki Tanioka; Kenji Kabashima; Yoshiki Miyachi
Journal:  Case Rep Dermatol       Date:  2014-11-29

Review 4.  Extracting information from the text of electronic medical records to improve case detection: a systematic review.

Authors:  Elizabeth Ford; John A Carroll; Helen E Smith; Donia Scott; Jackie A Cassell
Journal:  J Am Med Inform Assoc       Date:  2016-02-05       Impact factor: 4.497

  4 in total
  1 in total

1.  The incidences of other primary cancers in patients with mycosis fungoides and Sézary syndrome.

Authors:  Izabela Błażewicz; Berenika Olszewska; Marta Stawczyk-Macieja; Maciej Jaśkiewicz; Roman J Nowicki; Małgorzata Sokołowska-Wojdyło
Journal:  Postepy Dermatol Alergol       Date:  2021-05-22       Impact factor: 1.837

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.